Table 2.
Change in the main efficacy endpoints from baseline to end of treatment for STEP 1–6 and 8 [22,23,24,25,26,27,28].
| Parameter | STEP 1 | STEP 2 | STEP 3 | STEP 4 b | STEP 5 | STEP 6 | STEP 8 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide 2.4 mg | Placebo | Semaglutide 2.4 mg | Semaglutide 1 mg | Placebo | Semaglutide 2.4 mg | Placebo | Semaglutide 2.4 mg | Placebo | Semaglutide 2.4 mg | Placebo | Semaglutide 2.4 mg | Semaglutide 1.7 mg | Placebo | Semaglutide 2.4 mg | Liraglutide 3 mg | |
| Body weight change (%) | –14.9 | –2.4 | –9.6 | –7.0 | –3.4 | –16 | –5.7 | –7.9 | 6.9 | –15.2 | –2.6 | –13.2 | –9.6 | –2.1 | –15.8 | –6.4 |
| Participants with ≥5% weight loss (%) | 86.4 | 31.5 | 68.8 | 57.1 | 28.5 | 86.6 | 47.6 | 88.7 | 47.6 | 77.1 | 34.4 | 83 | 72 | 21 | 87.2 | 58.1 |
| Participants with ≥10% weight loss (%) | 69.1 | 12.0 | 45.6 | 28.7 | 8.2 | 75.3 | 75.3 | 79.0 | 20.4 | 61.8 | 13.3 | 61 | 42 | 5 | 70.9 | 25.6 |
| Participants with ≥15% weight loss (%) | 50.5 | 4.9 | 25.8 | 13.7 | 3.2 | 55.8 | 13.2 | 63.7 | 9.2 | 52.1 | 7.0 | 41 | 24 | 3 | 55.6 | 12.0 |
| WC (cm) | –13.54 | –4.13 | –9.4 | –6.7 | –4.5 | –14.6 | –6.3 | −6.4 | 3.3 | –14.4 | –5.2 | –11.1 | –7.7 | –1.8 | –13.2 | –6.6 |
| BMI (kg/m2) | –5.54 | –0.92 | –3.5 | –2.5 | –1.3 | –6.0 | –2.2 | −2.6 | 2.2 | NA | NA | –4.3 | –3.1 | –0.6 | NA | NA |
| CRP a (mg/dL) |
0.47 | 0.85 | 0.51 | 0.58 | 0.83 | –59.6 | –22.9 | NA | NA | –56.7 | –7.8 | 0.39 | 0.64 | 0.92 | –52.6 | –24.5 |
| SBP (mmHg) |
–6.16 | –1.06 | –3.9 | –2.9 | –0.5 | –6.3 | –1.6 | 0.5 | 4.4 | –5.7 | –1.6 | –11.0 | –12.0 | –5.0 | –5.7 | –2.9 |
| DBP (mmHg) |
–2.83 | –0.42 | –1.6 | –0.6 | –0.9 | –3.0 | –0.8 | 0.3 | 0.9 | –4.5 | –0.8 | –5 | –5 | –3 | –5.0 | –0.5 |
| HbA1c (%) |
–0.45 | –0.15 | –1.6 | –1.5 | –0.4 | –0.51 | –0.27 | −0.1 | 0.1 | –0.43 | –0.10 | –1.0 | –0.9 | 0.0 | –0.2 | –0.1 |
| FPG (mg/dL) |
–8.35 | –0.48 | –2.1 | –1.8 | –0.1 | –6.73 | –0.65 | −0.8 | 6.7 | –7.6 | 1.6 | –19.3 | –18.3 | 1.7 | –8.3 | –4.3 |
| TC a | 0.97 | 1.00 | 0.99 | 0.98 | 0.99 | –3.8 | 2.1 | 5 | 11 | NA | NA | 0.91 | 0.93 | 1.00 | –7.1 | –0.1 |
| LDL a | 0.97 | 1.01 | 1.00 | 0.99 | 1.00 | –4.7 | 2.6 | 1 | 8 | NA | NA | 0.86 | 0.90 | 0.95 | –6.5 | 0.9 |
| TG a | 0.78 | 0.93 | 0.78 | 0.83 | 0.91 | –22.5 | –6.5 | −6 | 15 | –19.0 | 3.7 | 0.79 | 0.78 | 1.05 | –20.7 | –11.0 |
a The data were presented as ratios of end of treatment to baseline for STEP 1, 2, and 6 and change % for STEP 3–5 and 8; b Change from week 20 (run-in period) to end of treatment. Abbreviations: WC, waist circumference; BMI, body mass index; CRP, C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; TC, total cholesterol; LDL, low-density lipoprotein; TG, triglyceride; NA, not available.